#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
Sign up for FREE Symplur Account and Get
- Create Transcripts with Custom Dates
- Get Custom Influencer Lists
- 3x Hashtag Search Results
| Profile | Tweet |
|---|---|
 | Brendon Stiles @BrendonStilesMD Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
 | Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
 | #LCSM Chat @lcsmchat RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
 | Henning Willers, MD @HenningWillers RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j… |
 | Jean Parks @geekbabe RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j… |
 | Jill Feldman @jillfeldman4 Hi it's Jill from Chicago. Looking forward to your recap of #WCLC19 @BrendonStilesMD #LCSM |
| Jean Parks @geekbabe RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Brendon Stiles @BrendonStilesMD To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi… |
| Brendon Stiles @BrendonStilesMD More info at https://t.co/Lx9qF406C9 #lcsm |
 | Bob Steele @steele_bob Good evening folks. Bob here in Greensboro, NC. Looking 4ward to hearing the news from Spain. #lcsm |
| Brendon Stiles @BrendonStilesMD @jillfeldman4 Looking forward to hearing your thoughts! #lcsm |
| Janet Freeman-Daily @JFreemanDaily Good evening all! Janet Freeman-Daily in Seattle. Looking forward to tonight's chat about #WCLC19 wrap-up! #LCSM |
| Brendon Stiles @BrendonStilesMD @GinaHollenbeck Hi Gina! #lcsm |
 | Lung Cancer Research Foundation @lcrf_org Excited about tonight’s #LCSM chat and catching up after this year's #wclc2019 with @BrendonStilesMD. Join us! |
 | Faces of Lung Cancer @LungCancerFaces Deana here in muggy Los Angeles. I’ll be tweeting from the @lcsmchat account tonight. #lcsm |
| Jean Parks @geekbabe Hi everyone stage IV almost 5 yrs, treated at @MGHCancerCenter #LCSM |
| Brendon Stiles @BrendonStilesMD We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
 | Tim Kruser @TimothyKruserMD Tim Kruser here. Looking forward to learning as had to miss WCLC19 given it was back-to-back with #ASTRO19 :( #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| Brendon Stiles @BrendonStilesMD @TimothyKruserMD Always love your input! #lcsm |
| #LCSM Chat @lcsmchat @steele_bob Evening, Bob! #lcsm |
 | Lung Cancer Sux @LungCancerSux @BrendonStilesMD @jillfeldman4 Hi! Glorianne in CT signing on! Great topic! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: More info at https://t.co/Lx9qF406C9 #lcsm |
 | Peggy Dennis @peggyddennis Peggy Dennis joining from Denver. Looking forward to the update. #lcsm |
| Brendon Stiles @BrendonStilesMD I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm |
| Brendon Stiles @BrendonStilesMD I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for @ppdCRO. These don’t affect opinions expressed tonight. #lcsm |
 | Jill Hamer-Wilson 🇨🇦 @JillHW Hi It's Jill from Ottawa Canada, looking forward to my first #LCSM chat, and the recap of #WCLC19 and #STARS19 |
| Brendon Stiles @BrendonStilesMD @LungCancerSux @jillfeldman4 So glad you are here! #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @GinaHollenbeck @BrendonStilesMD Hi Gina! Remember to include #LCSM in all your tweets so they'll appear in the Chat. |
| #LCSM Chat @lcsmchat @LungCancerSux @BrendonStilesMD @jillfeldman4 Hi Jill and Glorianne! #lcsm |
 | KC Dill @kasedill Hello from Houston, we are high and dry in the suburbs, lots of rain here.. #LCSM |
| Brendon Stiles @BrendonStilesMD @JillHW Hi Jill. A true STAR! #lcsm |
| Jean Parks @geekbabe RT @JFreemanDaily: Good evening all! Janet Freeman-Daily in Seattle. Looking forward to tonight's chat about #WCLC19 wrap-up! #LCSM |
| Henning Willers, MD @HenningWillers Hi all, @henningwillers here, also fresh back from ASTRO19 but wasn't at World Lung #lcsm |
 | Gina Hollenbeck @GinaHollenbeck Hi! Gina here. Stage IV, ALK Positive- President of ALK Positivw a Patient lead group of 1800+ patients and caregivers #lcsm |
| Brendon Stiles @BrendonStilesMD In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV |
| Jean Parks @geekbabe RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for… |
| #LCSM Chat @lcsmchat @BrendonStilesMD @GinaHollenbeck Welcome, Gina! Remember to include #lcsm in all your tweets. |
 | Deb Smith 🦋🌻🐚 @debsmithbeach Deb here, from NH. 8 yrs post dx, on Tagrisso almost 6 yrs, EGFR/T790. #lcsm |
| #LCSM Chat @lcsmchat @geekbabe @MGHCancerCenter Hey, Jean! #lcsm |
| Brendon Stiles @BrendonStilesMD @HenningWillers @HenningWillers Glad you made it! #lcsm Sorry to miss ASTRO! |
| #LCSM Chat @lcsmchat @TimothyKruserMD Welcome! #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV |
| #LCSM Chat @lcsmchat @peggyddennis Hi Peggy! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for… |
| #LCSM Chat @lcsmchat @JillHW Hey Jill! #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV |
 | Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @TimothyKruserMD: Cool work from @WashURadOnc w/ their friendly #tssmn colleagues. Developed algorithm to "assign" surgery vs SBRT. Amon… |
| Brendon Stiles @BrendonStilesMD #WCLC19 is a showcase for all of the latest news and advances in lung cancer #lcsm |
| #LCSM Chat @lcsmchat @kasedill Welcome! #lcsm |
 | Gina @EAustin1969 Gina and I’m actually here. Can’t wait to hear all the new stuff #LCSM |
| Brendon Stiles @BrendonStilesMD We will get started soon. First, a few reminders… #lcsm |
| #LCSM Chat @lcsmchat @HenningWillers Welcome! #lcsm |
| Brendon Stiles @BrendonStilesMD Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
| #LCSM Chat @lcsmchat @GinaHollenbeck Hey Gina! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV |
| Brendon Stiles @BrendonStilesMD If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #lcsm |
| #LCSM Chat @lcsmchat @debsmithbeach Hi Deb! #lcsm |
| Brendon Stiles @BrendonStilesMD I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
 | Charis Stacey 💙 @Charis_Stacey Charis here, from England. I lead Lung health checks programme. #LCSM |
 | Habitility @habitility #guaidoelparaco, #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, #jumatberkah, #wjsn, #veteran, #pintowards, #sisi_out, #bnk48, #choosemaxime, #chanbaek, #kcon2019thailand, \ https://t.co/kbjGZn9WvU |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #WCLC19 is a showcase for all of the latest news and advances in lung cancer #lcsm |
| #LCSM Chat @lcsmchat @EAustin1969 Hello Gina! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm |
| Brendon Stiles @BrendonStilesMD We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. Great group already! #lcsm |
 | NCI Cancer Stats @NCICancerStats The overall trends for new cases and deaths of lung and bronchial cancer have steadily declined since 1995. Learn more about this cancer from our stat fact sheet: https://t.co/BVqvN4e1pm #LCSM https://t.co/qFHrSzI6BL |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #lcsm |
| Brendon Stiles @BrendonStilesMD @Charis_Stacey Thanks for joining! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol… |
| Habitility @habitility Check out my Gig on Fiverr: render a site plan or landscape drawing https://t.co/FSPkI0OfD6 #guaidoelparaco, #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, #jumatberkah, |
| Brendon Stiles @BrendonStilesMD @EAustin1969 Glad you made it! #lcsm |
| #LCSM Chat @lcsmchat @Charis_Stacey Welcome, Charis! #lcsm |
| Habitility @habitility Check out my Gig on Fiverr: do architectural drawings or autocad floorplan https://t.co/HCG76yp3IU #guaidoelparaco, #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, |
| Brendon Stiles @BrendonStilesMD T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. Great… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm |
 | I Wear Masks @wildwestannie Hi, Betsy here, listening intently 😊 #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm |
| #LCSM Chat @lcsmchat @wildwestannie Hi Betsy! #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currently used. https://t.co/vWMM0ySB3y #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm |
 | puterimaya @puterimaya6 https://t.co/vKz0sMg9MI , #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, #jumatberkah, #wjsn, |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl… |
| Brendon Stiles @BrendonStilesMD T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl… |
| Janet Freeman-Daily @JFreemanDaily Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl… |
| Brendon Stiles @BrendonStilesMD Never smokers take note! #lcsm |
 | Shelly ET @shelly_et #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm |
| Jill Feldman @jillfeldman4 T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test to identify tumor markers is huge - fingers crossed! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl… |
 | Ricardo Bruges Maya @BrugesMaya RT @ChristianRolfo: Our paper is online! Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm |
| #LCSM Chat @lcsmchat @shelly_et Hey Shelly! Awesome haircut at #WCLC19 #lcsm |
| Brendon Stiles @BrendonStilesMD T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5J #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: Never smokers take note! #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm |
| Brendon Stiles @BrendonStilesMD @shelly_et Hi Shelly! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Never smokers take note! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co… |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5… |
| #LCSM Chat @lcsmchat RT @jillfeldman4: T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test… |
 | colleen ziegler @ZieglerColleen #lcsm a few minutes late...Colleen from Rochester joining |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm https://t.co/B7RsT… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5… |
| Janet Freeman-Daily @JFreemanDaily Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5… |
| Brendon Stiles @BrendonStilesMD T1. This study was also important because it included a high rate of low income patients and demonstrated high adherence rates, even in this high risk group. #lcsm https://t.co/Jud9FF3ULi |
| Bob Steele @steele_bob RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co… |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm |
| #LCSM Chat @lcsmchat @ZieglerColleen Hi Colleen! #lcsm |
 | Lillian Leigh @ProjectBreath RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM |
| Shelly ET @shelly_et Hello! Thanks! I'm thinking about a color for my mohawk... Any suggestions?? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N… |
| Brendon Stiles @BrendonStilesMD T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to improve detection rates and to guide screening intervals. #lcsm https://t.co/YiqIvDo6FP |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere… |
| Bob Steele @steele_bob RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere… |
| Brendon Stiles @BrendonStilesMD RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp… |
| Lung Cancer Research Foundation @lcrf_org Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on this front. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm |
| Charis Stacey 💙 @Charis_Stacey Need to develop real world implementation evidence. Uptake and outcome. Smoking cessation a vital component. #LCSM |
| Janet Freeman-Daily @JFreemanDaily More from a #WCLC19 plenary about #lungcancer #screening. #lcsm |
| #LCSM Chat @lcsmchat I’m partial to purple (Deana) #lcsm |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5… |
| Lillian Leigh @ProjectBreath RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc |
| Bob Steele @steele_bob RT @Charis_Stacey: Need to develop real world implementation evidence. Uptake and outcome. Smoking cessation a vital component. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @IASLC: IASLC Board Member @RamalingamMD presents on disparities in LC, highlighting the importance of #tobaccocontrol, the gaps in edu.… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp… |
| #LCSM Chat @lcsmchat RT @lcrf_org: Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on th… |
| Bob Steele @steele_bob RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm |
| #LCSM Chat @lcsmchat RT @Charis_Stacey: Need to develop real world implementation evidence. Uptake and outcome. Smoking cessation a vital component. #LCSM |
| Brendon Stiles @BrendonStilesMD T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc |
 | Nava Rodrigues, D @daninava RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm |
| Jean Parks @geekbabe @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM |
| Brendon Stiles @BrendonStilesMD @Charis_Stacey Totally agree. Scottish study went a long way towards this. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm |
| #LCSM Chat @lcsmchat RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM |
| Brendon Stiles @BrendonStilesMD RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM |
| Bob Steele @steele_bob RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM |
| KC Dill @kasedill RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl… |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N… |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere… |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM |
| Lung Cancer Research Foundation @lcrf_org RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test… |
 | OurWarOnCancer @OurWarOnCancer RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp… |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @TimAllenMDJD: "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm https://t.co/B7RsT… |
| Brendon Stiles @BrendonStilesMD @HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention... #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm https://t.co/B7RsT… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Personalized Prevention: the new personalized medicine #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl… |
| OurWarOnCancer @OurWarOnCancer RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere… |
| Brendon Stiles @BrendonStilesMD RT @lcrf_org: Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on th… |
| Deb Smith 🦋🌻🐚 @debsmithbeach @BrendonStilesMD I’m glad to see non smokers considered! #LCSM |
| Bob Steele @steele_bob RT @TimAllenMDJD: Personalized Prevention: the new personalized medicine #lcsm https://t.co/0OXR2XgHin |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @jillfeldman4: T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test… |
| Jean Parks @geekbabe @TimAllenMDJD @BrendonStilesMD P53 would have caught me before I was stage IV #LCSM |
 | Laura Greco @lgreco_ny Laura here,late. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5… |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: Never smokers take note! #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: @HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention.… |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm |
| KC Dill @kasedill @lgreco_ny Hi Laura #LCSM |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. Great… |
| Brendon Stiles @BrendonStilesMD T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere… |
| OurWarOnCancer @OurWarOnCancer RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl… |
| Faces of Lung Cancer @LungCancerFaces If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there. |
| Brendon Stiles @BrendonStilesMD T2 coming soon! #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm |
| Tim Kruser @TimothyKruserMD T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase screening rates! #lcsm |
| Brendon Stiles @BrendonStilesMD RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there. |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm |
| #LCSM Chat @lcsmchat @lgreco_ny Hey Laura! #lcsm |
| Brendon Stiles @BrendonStilesMD T2 will need some oncologists and pathologists! #lcsm |
| Bob Steele @steele_bob RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention.… |
| OurWarOnCancer @OurWarOnCancer RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM |
| Gina Hollenbeck @GinaHollenbeck @BrendonStilesMD A mobile unit was on display for screening in rural areas. Wish it wasn’t just for smokers. #WCLC2019, #lcsm https://t.co/4L7TemzWnR |
| Brendon Stiles @BrendonStilesMD T2. What is important to know about molecular testing? Is universal testing coming? #lcsm |
| Charis Stacey 💙 @Charis_Stacey Agree, Nelson paper needed. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j… |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there. |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm |
| #LCSM Chat @lcsmchat RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr… |
| Deb Smith 🦋🌻🐚 @debsmithbeach @BrendonStilesMD T1: What factors are involved for nonsmokers? I’m curious if I would qualify for screening. #LCSM |
 | Lecia Sequist, MD, MPH @LeciaSequist Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm |
| KC Dill @kasedill RT @BrendonStilesMD: T2 will need some oncologists and pathologists! #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Personalized Prevention: the new personalized medicine #lcsm https://t.co/0OXR2XgHin |
| Brendon Stiles @BrendonStilesMD T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcsm https://t.co/qMRwz4DQNl |
| Bob Steele @steele_bob RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc |
| Brendon Stiles @BrendonStilesMD RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm |
| Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm |
| Lung Cancer Sux @LungCancerSux RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr… |
| Janet Freeman-Daily @JFreemanDaily RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there. |
 | Katie Brown @brownbeansprout RT @BrendonStilesMD: T2. What is important to know about molecular testing? Is universal testing coming? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr… |
| Brendon Stiles @BrendonStilesMD @LeciaSequist Always amazing! Thanks for joining! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD NGS FTW #lcsm |
 | Bill Brady @sharemyopinion @LungCancerFaces #lcsm |
| Lung Cancer Research Foundation @lcrf_org One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm |
| Brendon Stiles @BrendonStilesMD T2. There is remarkable variability in what individual institutions test for. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @GinaHollenbeck: @BrendonStilesMD A mobile unit was on display for screening in rural areas. Wish it wasn’t just for smokers. #WCLC2019,… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. What is important to know about molecular testing? Is universal testing coming? #lcsm |
| Faces of Lung Cancer @LungCancerFaces @TimothyKruserMD @VPrasadMDMPH You’re a Doc after my own heart, Tim. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @LeciaSequist: Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night.… |
| Janet Freeman-Daily @JFreemanDaily @LeciaSequist Welcome Lecia! #LCSM |
| Brendon Stiles @BrendonStilesMD T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Lives depend upon it. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Back atcha @LungCancerFaces #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs… |
| Bob Steele @steele_bob RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm |
 | Chandan K Das MD ,DM @ckdasoncology RT @KadrinWilfong: @PeerView Live at #ASTRO19: Dr. Kathryn Beal, @PatelOncology , and @BrainTumorDoc share an algorithm for management of n… |
 | Ehsan H. Balagamwala @DrEHBalagamwala RT @JAMAOnc: Rand ph2 trial of pembro vs stereotactic body radiation therapy (SBRT) to a lesion before pembro for adv NSCLC shows doubling… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2 will need some oncologists and pathologists! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs… |
| Brendon Stiles @BrendonStilesMD T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back – especially in developing countries. #lcsm |
| #LCSM Chat @lcsmchat RT @GinaHollenbeck: @BrendonStilesMD A mobile unit was on display for screening in rural areas. Wish it wasn’t just for smokers. #WCLC2019,… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. What is important to know about molecular testing? Is universal testing coming? #lcsm |
| Laura Greco @lgreco_ny @kasedill @lgreco_ny #lcsm |
| #LCSM Chat @lcsmchat @LeciaSequist Welcome! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Need evidence-based standardization. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD @DCarboneMD @ChristianRolfo That session went by REALLY fast. I'll have to rewatch it a few times to absorb everything. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: NGS FTW #lcsm https://t.co/QewB9ywD45 |
| Brendon Stiles @BrendonStilesMD T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3 |
| #LCSM Chat @lcsmchat @sharemyopinion @LungCancerFaces Welcome, Bill. #lcsm |
| #LCSM Chat @lcsmchat RT @lcrf_org: One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm |
| Shelly ET @shelly_et I'm glad to see it is not in the shape of a cigarette. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm |
| Bob Steele @steele_bob RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm |
| I Wear Masks @wildwestannie RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Liv… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3 |
| Brendon Stiles @BrendonStilesMD T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm |
| #LCSM Chat @lcsmchat RT @shelly_et: I'm glad to see it is not in the shape of a cigarette. #lcsm https://t.co/MVYdlmFbR3 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV |
| Brendon Stiles @BrendonStilesMD T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm |
| Bob Steele @steele_bob RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https… |
| Lung Cancer Sux @LungCancerSux RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https… |
| Bob Steele @steele_bob RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for certain biomarkers than others. No one test is perfect for all. Might be good to perform both liquid biopsy and tissue biopsy if possible. #LCSM |
| Brendon Stiles @BrendonStilesMD T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @ChristianRolfo #lcsm https://t.co/PAlpXCfgqR |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #StandardOfCare #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @lcrf_org: One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3 |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm |
| Faces of Lung Cancer @LungCancerFaces Welcome, Sue! Glad you’re here. If you want to tweet during the chat, remember to include the hashtag #lcsm. |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm |
| Brendon Stiles @BrendonStilesMD RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi… |
| Laura Greco @lgreco_ny RT @BrendonStilesMD: T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and often much more impactful! #lcsm https://t.co/iwIlXbgvaf |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Liv… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back… |
| Faces of Lung Cancer @LungCancerFaces #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj |
| Deb Smith 🦋🌻🐚 @debsmithbeach RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3 |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https… |
| Brendon Stiles @BrendonStilesMD And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ |
 | Chris Martin @CMPR #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ |
| Brendon Stiles @BrendonStilesMD T3 on way! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and… |
| #LCSM Chat @lcsmchat RT @LungCancerFaces: #lcsm https://t.co/cmH4zKXlNr |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X |
 | Dr. Jan Marie Eberth @jmeberth Hi #lcsm crew! Hated to miss @IASLC meeting and was hoping to hear @BrendonStilesMD’s take on the best of the best! Nice to see you all... |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD And yet payment for biomarker testing remains problematic! Patients usually don't know this. #lcsm #CBCIV |
| #LCSM Chat @lcsmchat @CMPR Welcome, Chris! #lcsm |
| Brendon Stiles @BrendonStilesMD T3. What was new at #WCLC19 regarding immunotherapy? #lcsm |
| KC Dill @kasedill RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and… |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X |
| Brendon Stiles @BrendonStilesMD @jmeberth @IASLC HELLO! Hope all is well! #lcsm |
| #LCSM Chat @lcsmchat @jmeberth @IASLC @BrendonStilesMD Thanks for joining! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X |
 | tauromaquiaficionado @taurinaficion RT @IASLC: Join Latin America’s largest gathering of clinicians, researchers and scientists in the field of #LungCancer and thoracic oncolo… |
 | Dave Bjork @bjork5 @BrendonStilesMD Just joining...sorry I’m late! Dave here from Boston 😊 #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: And yet payment for biomarker testing remains problematic! Patients usually don't know this. #lcsm #CBCIV https://t.co/Hz… |
 | Drew Moghanaki @DrewMoghanaki RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co… |
| Jean Parks @geekbabe What’s sad is small hospitals who don’t do much molecular testing #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. What was new at #WCLC19 regarding immunotherapy? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Still very complicated. #lcsm |
 | Jose F. Corona-Cruz MD @drcoronacruz #LCSM Late! But wanting to join the conversation José from Mexico City |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. What was new at #WCLC19 regarding immunotherapy? #lcsm |
| KC Dill @kasedill RT @TimAllenMDJD: And yet payment for biomarker testing remains problematic! Patients usually don't know this. #lcsm #CBCIV https://t.co/Hz… |
| Brendon Stiles @BrendonStilesMD T3. There were several important immunotherapy presentations at #WCLC19 #lcsm |
 | Enlightening Results 😷 @GraceCordovano RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer… |
| #LCSM Chat @lcsmchat @bjork5 @BrendonStilesMD Hey, Dave! You’ve been a busy guy. #lcsm |
| Brendon Stiles @BrendonStilesMD @bjork5 Will take you any time! Thanks for joining! #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm |
| #LCSM Chat @lcsmchat RT @geekbabe: What’s sad is small hospitals who don’t do much molecular testing #LCSM https://t.co/BRBrJLm5up |
| Brendon Stiles @BrendonStilesMD @drcoronacruz Thanks for joining! #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Still very complicated. #lcsm https://t.co/vkbjYwOpgp |
| Brendon Stiles @BrendonStilesMD T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very challenging cancer to treat. #lcsm |
| #LCSM Chat @lcsmchat @drcoronacruz Hola! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Still very complicated. #lcsm https://t.co/vkbjYwOpgp |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha… |
| Dave Bjork @bjork5 @lcsmchat @BrendonStilesMD Ha! We’re all out there... in this together! #lcsm #clinicaltrials |
| Jean Parks @geekbabe RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha… |
| Brendon Stiles @BrendonStilesMD T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/bYfP0OnJ0K |
| Brendon Stiles @BrendonStilesMD T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm |
| Dr. Jan Marie Eberth @jmeberth @BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives to get folks tested and treated based on evidence based guidelines. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm |
| #LCSM Chat @lcsmchat RT @jmeberth: @BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives… |
| Brendon Stiles @BrendonStilesMD T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm |
| Brendon Stiles @BrendonStilesMD T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effect in major study presented at #WCLC19 https://t.co/VmgMmGX7N6 #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm |
| Brendon Stiles @BrendonStilesMD #lcsm |
| #LCSM Chat @lcsmchat @CMPR We 💖 IASLC. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha… |
| Brendon Stiles @BrendonStilesMD T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable responses. https://t.co/f16yTGVQsN #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @jmeberth: @BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives… |
| Bob Steele @steele_bob RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst |
| Jean Parks @geekbabe RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD Agree totally. #lcsm |
 | Sewanti Limaye 🇮🇳🇺🇸 @SewantiLimaye RT @JAMAOnc: Rand ph2 trial of pembro vs stereotactic body radiation therapy (SBRT) to a lesion before pembro for adv NSCLC shows doubling… |
| Shelly ET @shelly_et @geekbabe @lcsmchat Or the wrong kind of testing. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec… |
 | Lizzie Barclay 💙 @LizzieBarclay1 @BrendonStilesMD T1. Attended #WCLC19 - great to see so much focus on lung cancer screening, including optimising patient uptake. Would like to see more discussion on optimising resources to achieve sustainable screening programs. NHS radiology departments already under strain. #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst |
| KC Dill @kasedill RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #Hope #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst |
| Dave Bjork @bjork5 #PrecisionMedicine #LCSM |
| #LCSM Chat @lcsmchat RT @LizzieBarclay1: @BrendonStilesMD T1. Attended #WCLC19 - great to see so much focus on lung cancer screening, including optimising patie… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon… |
| Jose F. Corona-Cruz MD @drcoronacruz A todos los interesados en discutir lo más relevante del #WCLC19, sigan el chat con el hashtag #LCSM ahora mismo se está poniendo muy interesante |
| Brendon Stiles @BrendonStilesMD T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage III group! If holds will be new standard of care for IIIA. #lcsm |
| Jean Parks @geekbabe RT @LeciaSequist: Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night.… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Jury's still out on TMB. #lcsm |
| Tim Kruser @TimothyKruserMD T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAlexLouie #lcsm |
| Brendon Stiles @BrendonStilesMD T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over 4x with chemo. Is cure possible? https://t.co/85aIzpvHFI #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl… |
| Lung Cancer Sux @LungCancerSux RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon… |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: A todos los interesados en discutir lo más relevante del #WCLC19, sigan el chat con el hashtag #LCSM ahora mismo se está… |
 | Matthew Katz, MD 🇺🇸 @subatomicdoc RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec… |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD What do you think Tim? #lcsm |
 | TranslationalGenomic @TGEG_ResDx RT @UmbertoMalapel1: @ChristianRolfo on Liquid Biopsy @IASLC @OncoAlert @isliquidbiopsy https://t.co/KAH4bpElKf |
| Henning Willers, MD @HenningWillers T3 what about neoadjuvant IO + chemo? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage II… |
 | Biniam Kidane @biniamkidaneMD @LizzieBarclay1 @BrendonStilesMD I wish I could’ve been there. Interested to see experiences in this exact issue across different healthcare systems. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Jury's still out on TMB. #lcsm https://t.co/fRlldZm2s2 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Solid. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl… |
 | Stephen V Liu @StephenVLiu T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR #NSCLC identified and 36% never received an EGFR TKI. Survival 21 months with TKI vs 13.3 without. #LCSM https://t.co/zJeL9UtpYe |
| #LCSM Chat @lcsmchat RT @drcoronacruz: A todos los interesados en discutir lo más relevante del #WCLC19, sigan el chat con el hashtag #LCSM ahora mismo se está… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over… |
| TranslationalGenomic @TGEG_ResDx RT @IASLC: Liquid biopsy has recently generated great interest as a minimally invasive diagnostic assay to overcome the challenges of tissu… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage II… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Jury's still out on TMB. #lcsm https://t.co/fRlldZm2s2 |
| #LCSM Chat @lcsmchat RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD All kinds of combinations are being studied. It's exploded! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Solid. #lcsm https://t.co/Lp1BzSRoH1 |
| #LCSM Chat @lcsmchat RT @HenningWillers: T3 what about neoadjuvant IO + chemo? #lcsm |
| Brendon Stiles @BrendonStilesMD @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose SBRT over chemo any day! Our trial with Durva + 8Gy x 3 was presented at #WCLC19. Encouraging results. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: All kinds of combinations are being studied. It's exploded! #lcsm https://t.co/mteduvc17y |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Solid. #lcsm https://t.co/Lp1BzSRoH1 |
| #LCSM Chat @lcsmchat RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: All kinds of combinations are being studied. It's exploded! #lcsm https://t.co/mteduvc17y |
| Laura Greco @lgreco_ny @HenningWillers It's so interesting... is maybe sequencing everything? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose… |
| Brendon Stiles @BrendonStilesMD @TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particular. Neoadjuvant IO makes much more sense to me than adjuvant! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose… |
| KC Dill @kasedill T3 Nivolumab was a game changer for me! #LCSM |
| Jose F. Corona-Cruz MD @drcoronacruz El screening en Cáncer de Pulmón salva vidas, el estrato socio económico no parece ser una barrera para su implementación y apego #LCSM |
| Tim Kruser @TimothyKruserMD RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose… |
| Brendon Stiles @BrendonStilesMD T4 just around the corner - new targets! #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD T3 we are with you 👍 #radonc #Sabr #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particula… |
 | Jose Pacheco @LungCancerDr RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR… |
| Lung Cancer Research Foundation @lcrf_org @TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV |
| Jean Parks @geekbabe RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over… |
| Brendon Stiles @BrendonStilesMD @lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particula… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @lgreco_ny: @HenningWillers It's so interesting... is maybe sequencing everything? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose… |
| Matthew Katz, MD 🇺🇸 @subatomicdoc RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particula… |
| Brendon Stiles @BrendonStilesMD T4. Are there any exciting new targets being investigated in lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @drcoronacruz: El screening en Cáncer de Pulmón salva vidas, el estrato socio económico no parece ser una barrera para su implementación… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @lcrf_org: @TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD NGS FTW #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV https://t… |
| Laura Greco @lgreco_ny Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonStilesMD @lcrf_org |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm |
| KC Dill @kasedill RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over… |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: NGS FTW #lcsm https://t.co/1hYLgc1wso |
| Gina @EAustin1969 T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm |
| #LCSM Chat @lcsmchat RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt… |
| Jose F. Corona-Cruz MD @drcoronacruz La biopsia líquida esta más cerca de ser nuestra primera opción al abordar a un paciente con cáncer de pulmón El fin de la era "the tissue is the issue" ? #LCSM |
| Brendon Stiles @BrendonStilesMD T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm |
| Jean Parks @geekbabe @BrendonStilesMD Have been on Opdivo for well over 4 yrs, patients with residual cancer need a maintenance tx plan #LCSM |
| Henning Willers, MD @HenningWillers RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt… |
| Brendon Stiles @BrendonStilesMD @EAustin1969 Without a doubt! #lcsm |
| #LCSM Chat @lcsmchat RT @EAustin1969: T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-small cell lung cancer. https://t.co/GY6RDUXkmi #lcsm |
| Dave Bjork @bjork5 #PrecisionMedicine #LCSM |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm |
| Brendon Stiles @BrendonStilesMD LIBRETTO! #lcsm https://t.co/at7CJ8sTGf |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm |
| Shelly ET @shelly_et Ditto!!! #lcsm |
| Dave Bjork @bjork5 @BrendonStilesMD What about RET? #LCSM |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-s… |
| Jose F. Corona-Cruz MD @drcoronacruz El costo de las pruebas moleculares para seleccionar el mejor tratamiento en Cáncer de Pulmón no es excusa para no realizarlo Aún en países de bajos recursos existe manera de realizarlo gratis para el paciente #LCSM |
| Jean Parks @geekbabe RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf |
| Drew Moghanaki @DrewMoghanaki Dr. Drew is in finally the house. Just landed in Minneapolis for #AVAHO19 meeting where we are talking about each of these topics as they relate to Veterans with cancer. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #lcsm |
| KC Dill @kasedill @EAustin1969 This is hope!!! #LCSM |
| Biniam Kidane @biniamkidaneMD @BrendonStilesMD T4: many new targets indeed! Having sadly missed #WCLC19, I’m hoping to catch up on what I missed there #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-s… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: El screening en Cáncer de Pulmón salva vidas, el estrato socio económico no parece ser una barrera para su implementación… |
| Jill Hamer-Wilson 🇨🇦 @JillHW #MoreResearch #MoreSurvivors #ResearchMatters #LCSM |
 | Ricardo González Woge @ricardowoge RT @drcoronacruz: La biopsia líquida esta más cerca de ser nuestra primera opción al abordar a un paciente con cáncer de pulmón El fin de… |
| Brendon Stiles @BrendonStilesMD @bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-small cell lung cancer. https://t.co/GY6RDUXkmi |
| KC Dill @kasedill RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @lcrf_org: @TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm |
| #LCSM Chat @lcsmchat RT @drcoronacruz: El costo de las pruebas moleculares para seleccionar el mejor tratamiento en Cáncer de Pulmón no es excusa para no realiz… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV https://t… |
| Bob Steele @steele_bob RT @geekbabe: @BrendonStilesMD Have been on Opdivo for well over 4 yrs, patients with residual cancer need a maintenance tx plan #LCSM |
| Stephen V Liu @StephenVLiu T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second line CheckMate studies of nivolumab and 3y follow up from KEYNOTE 024, with first line pembrolizumab (with 3y OS rate of 44%!) #LCSM https://t.co/KhEaOLGhAV |
| Dave Bjork @bjork5 This!! Support #lungcancer research. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #… |
| Brendon Stiles @BrendonStilesMD T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: @bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion… |
| Lung Cancer Research Foundation @lcrf_org RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8 |
| Jean Parks @geekbabe RT @HenningWillers: @BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion… |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm |
| #LCSM Chat @lcsmchat RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin… |
| Bob Steele @steele_bob RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #… |
| Brendon Stiles @BrendonStilesMD @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand interplay. #lcsm |
| #LCSM Chat @lcsmchat RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm |
 | Ken @TheDura01 RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst |
| Jose F. Corona-Cruz MD @drcoronacruz La inmunoterapia con durvalumab mejoró la supervivencia en Cáncer de Pulmón de Células Pequeñas Mucho camino por recorrer en esta variante histológica, pero el estudio CASPIAN representa un gran avance #LCSM |
| Jean Parks @geekbabe RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin… |
| Henning Willers, MD @HenningWillers RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin… |
| Brendon Stiles @BrendonStilesMD T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlcIWnoT |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Lots of research right now about this. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte… |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc… |
| Brendon Stiles @BrendonStilesMD T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc… |
| Bob Steele @steele_bob RT @TimAllenMDJD: Lots of research right now about this. #lcsm https://t.co/ALAMi84sPz |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm |
| Dave Bjork @bjork5 @BrendonStilesMD What about BLU667? Promising? #LCSM #clinicaltrials |
 | Narjust Duma, M.D. @NarjustDumaMD @StephenVLiu @IASLC I agree! #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Huge. #lcsm #CBCIV |
| Brendon Stiles @BrendonStilesMD T4. As mentioned earlier, moving immunotherapy or targeted therapy into earlier stage disease is also hot. #lcsm |
| Laura Greco @lgreco_ny IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @bjork5 #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt… |
| Jean Parks @geekbabe @StephenVLiu @IASLC 4 yrs & 4 months on Nivo, stage IV, still working #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm |
| Narjust Duma, M.D. @NarjustDumaMD @BrendonStilesMD Together we rise #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @EAustin1969: T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK, and ROS1. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: La biopsia líquida esta más cerca de ser nuestra primera opción al abordar a un paciente con cáncer de pulmón El fin de… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm |
| Jill Hamer-Wilson 🇨🇦 @JillHW #Selpercatinib in patients with #RET fusion positive NSCLC #lungcancer #LCSM #WCLC19 @IASLC @OttawaHospital @OttawaMedOnc |
| #LCSM Chat @lcsmchat RT @lgreco_ny: IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @… |
| Brendon Stiles @BrendonStilesMD @lgreco_ny @bjork5 It is a great question. #lcsm |
 | Pamela Q Fernandes @PamelaQFerns RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/… |
| Jean Parks @geekbabe RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte… |
| Bob Steele @steele_bob RT @JillHW: #Selpercatinib in patients with #RET fusion positive NSCLC #lungcancer #LCSM #WCLC19 @IASLC @OttawaHospital @OttawaMedOnc https… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-s… |
| Jose F. Corona-Cruz MD @drcoronacruz La inmunoterapia se está moviendo a las etapas no metástasicas del cáncer de pulmón Los esquemas previos a la cirugía prometen mejorar la supervivencia de estos pacientes La respuesta patológica es un buen predictor de que tan efectivo puede ser esta propuesta #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm |
| Brendon Stiles @BrendonStilesMD @NarjustDumaMD You said it right! Thanks for joining! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf |
| Jose F. Corona-Cruz MD @drcoronacruz RT @BrendonStilesMD: T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage II… |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: El costo de las pruebas moleculares para seleccionar el mejor tratamiento en Cáncer de Pulmón no es excusa para no realiz… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,… |
| Tim Kruser @TimothyKruserMD @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001, showing even more impressive memory sparing with hippocampal avoidance for those pts where whole brain RT is needed. @NRGonc h/t @SeanSachdevMD for the pics! @BrainTumorInst #lcsm https://t.co/zO5UIMKj76 |
| Jean Parks @geekbabe RT @JillHW: #Selpercatinib in patients with #RET fusion positive NSCLC #lungcancer #LCSM #WCLC19 @IASLC @OttawaHospital @OttawaMedOnc https… |
| KC Dill @kasedill @geekbabe @StephenVLiu @IASLC Amazing! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #… |
| Brendon Stiles @BrendonStilesMD Here comes T5! #lcsm |
| #LCSM Chat @lcsmchat RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,… |
| Brendon Stiles @BrendonStilesMD T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy challenge. Immunotherapy may ultimately prevail. #lcsm #CBCIV |
| Jean Parks @geekbabe RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,… |
| Janet Freeman-Daily @JFreemanDaily RT @HenningWillers: @BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm |
| Jose F. Corona-Cruz MD @drcoronacruz El seguimiento a largo plazo de los primeros ensayos con inmunoterapia mostraron una supervivencia nunca antes vista para Cáncer de Pulmón Curación de la enfermedad metástasica? O se convertirá en una enfermedad crónica? #LCSM |
| Biniam Kidane @biniamkidaneMD @JillHW @BrendonStilesMD Hi @JillHW ! Hi everyone...just decided to sneak in and learn 😀#lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm |
| Henning Willers, MD @HenningWillers RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,… |
| Laura Greco @lgreco_ny RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,… |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy… |
| Janet Freeman-Daily @JFreemanDaily RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8 |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm |
| Brendon Stiles @BrendonStilesMD T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07oQJ5j |
| Shelly ET @shelly_et Yes, keep them coming! We need more options. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte… |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: La inmunoterapia con durvalumab mejoró la supervivencia en Cáncer de Pulmón de Células Pequeñas Mucho camino por recorr… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #NoStigma #lcsm |
| KC Dill @kasedill RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Drew Moghanaki @DrewMoghanaki RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Lots of research right now about this. #lcsm https://t.co/ALAMi84sPz |
| Biniam Kidane @biniamkidaneMD RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Brendon Stiles @BrendonStilesMD T5. Special thanks to @KAdvocate_LCAM and to @BairdAM who really made the program happen. And of course to @iaslc #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @bjork5: @BrendonStilesMD What about BLU667? Promising? #LCSM #clinicaltrials |
| Ricardo Bruges Maya @BrugesMaya RT @IASLC: Liquid biopsy has recently generated great interest as a minimally invasive diagnostic assay to overcome the challenges of tissu… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Huge. #lcsm #CBCIV https://t.co/0aQGKj9VSZ |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Lung Cancer Research Foundation @lcrf_org STARS: What an amazing program at this year's #wclc2019 @IASLC #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. As mentioned earlier, moving immunotherapy or targeted therapy into earlier stage disease is also hot. #lcsm |
| Laura Greco @lgreco_ny Yes! A lot of posters looking at other mechanisms of growth re ALK. #lcsm @HenningWillers @BrendonStilesMD |
 | Denise Cutlip @dennycee Sorry to be so late #lcsm |
| Janet Freeman-Daily @JFreemanDaily T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advocates (PRAs) & 5 Mentors to #WCLC19 to learn about lung cancer research. Doing it again in 2020 with more PRAs! Learn more here: https://t.co/jHlTI7YGds #LCSM https://t.co/eoqF22fJme |
| Jill Hamer-Wilson 🇨🇦 @JillHW Long term IO #hope #LCSM #WCLC19 #lungcancer #immunotherapy @OttawaHospital @OttawaCancer |
| #LCSM Chat @lcsmchat Also @JFreemanDaily #lcsm |
| Brendon Stiles @BrendonStilesMD T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: Susan McCullough, @kamacintosh, @lgreco_ny, @shelly_et, and @boldcaleb. #lcsm https://t.co/hJVVFM9GQW |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD I missed readouts from adjuvant trials with targeted therapies--were there any at #WCLC19? #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S… |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo… |
| Jean Parks @geekbabe Happy to serve as your human mouse model when needed. Always do blood draws & give extra biopsy samples #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @lgreco_ny: IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @… |
| KC Dill @kasedill RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @lgreco_ny @bjork5 It is a great question. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #LikeABoss #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: T5. Special thanks to @KAdvocate_LCAM and to @BairdAM who really made the program happen. And of course to @iaslc #lc… |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: La inmunoterapia se está moviendo a las etapas no metástasicas del cáncer de pulmón Los esquemas previos a la cirugía p… |
| Janet Freeman-Daily @JFreemanDaily T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep should read the #WCLC19 speech delivered by ALK+ NSCLC patient activist and clinical trial Olympian Linnea Olson. #LCSM #clinicaltrials https://t.co/loZAmpfgH3 |
| Brendon Stiles @BrendonStilesMD T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater. Thanks @IASLC. #lcsm https://t.co/m25CoQGRG9 |
| Laura Greco @lgreco_ny I can't wait to see what this will be come to be! #stars19 @BrendonStilesMD #lcsm |
| Jose F. Corona-Cruz MD @drcoronacruz RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo… |
| Jean Parks @geekbabe RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater.… |
| Drew Moghanaki @DrewMoghanaki T5: Can someone explain how radiation oncologists can get involved with STARS? #lcsm |
| Biniam Kidane @biniamkidaneMD RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo… |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep… |
| Jean Parks @geekbabe RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S… |
| Dave Bjork @bjork5 Love this. Thanks @JFreemanDaily 🙌 #LCSM #WCLC19 |
| Biniam Kidane @biniamkidaneMD RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S… |
| Janet Freeman-Daily @JFreemanDaily RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep… |
| KC Dill @kasedill @BrendonStilesMD Loved hearing their updates! #LCSM |
| Biniam Kidane @biniamkidaneMD RT @BrendonStilesMD: T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater.… |
| Brendon Stiles @BrendonStilesMD Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and remember why we do what we do when patients are there. #lcsm https://t.co/lAAZQD7Yzz |
| Shelly ET @shelly_et It is an honor to be involved in this program!! #lcsm |
| Jean Parks @geekbabe RT @JFreemanDaily: @BrendonStilesMD I missed readouts from adjuvant trials with targeted therapies--were there any at #WCLC19? #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm |
| KC Dill @kasedill RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo… |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy… |
| Laura Greco @lgreco_ny RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S… |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: El seguimiento a largo plazo de los primeros ensayos con inmunoterapia mostraron una supervivencia nunca antes vista para… |
| Gina Hollenbeck @GinaHollenbeck @BrendonStilesMD There was a new assay test for ROS1 developed by Ventana. Relatively cheap and you get the results in 2 days. I wish we could have a comprehensive genomic panel assay;) #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07… |
| Laura Greco @lgreco_ny RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,… |
| Brendon Stiles @BrendonStilesMD @DrewMoghanaki Simply admit that surgery is better than SBRT and you are in... Or if easier, volunteer to help! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Special thanks to @KAdvocate_LCAM and to @BairdAM who really made the program happen. And of course to @iaslc #lc… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb… |
| Jill Feldman @jillfeldman4 T5 So sorry...talking one of my college kids off the ledge. Will have to catch up later, but STARS was amazing thanks to @BairdAM @IASLC @JFreemanDaily @KAdvocate_LCAM Can't wait to see how the program expands. We need more educated research advocates #LCSM |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily I didn't see any big ones either. None that I am aware of. #lcsm |
| Drew Moghanaki @DrewMoghanaki @shelly_et I want to have this honor too! Where can I sign up? #lcsm @jillfeldman4 |
| Janet Freeman-Daily @JFreemanDaily RT @lcrf_org: STARS: What an amazing program at this year's #wclc2019 @IASLC #lcsm |
| Brendon Stiles @BrendonStilesMD Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| Dave Bjork @bjork5 I agree #LCSM @J2Novack @1111linno 🙌 |
| Sue McCullough @SueMcCu30398663 Sue Mc, I am here, just watching 💚#LCSM |
| Brendon Stiles @BrendonStilesMD Please share your closing thoughts! #lcsm |
| Matthew Katz, MD 🇺🇸 @subatomicdoc RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt… |
| Brendon Stiles @BrendonStilesMD Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S… |
| Brendon Stiles @BrendonStilesMD @SueMcCu30398663 Hi Sue! #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater.… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Thank you, @BrendonStilesMD, for hosting this great #lcsm session. It was a privilege to participate. |
| Laura Greco @lgreco_ny Are you ever home? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please share your closing thoughts! #lcsm |
| Brendon Stiles @BrendonStilesMD #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm https://t.co/kjR3NAeD7x |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm |
| Lung Cancer Research Foundation @lcrf_org Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily! |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @lcrf_org: Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily! |
 | IASLC @IASLC The registration deadline for the IASLC 2019 North America Conference on Lung Cancer has been extended to September 25! Register now to learn about the latest developments in #LungCancer prevention, detection and care at #NACLC19 --> https://t.co/1b4iyU3MSw #LCSM https://t.co/HsSRzyXSkO |
| Gina Hollenbeck @GinaHollenbeck @BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward to seeing how the stars use the information learned in Barcelona #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb… |
| Bob Steele @steele_bob RT @lcrf_org: Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily! |
| I Wear Masks @wildwestannie Tomorrow marks the 21st anniversary of my Mom’s death from lung cancer. Treatment options and current research now weren’t even dreams then! Imagine where we’ll be in another 21 years! ❤️ #lcsm |
 | Elad Sharon @EladSharonMD RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin… |
| Janet Freeman-Daily @JFreemanDaily @DrewMoghanaki Talk to me or @KAdvocate_LCAM! #LCSM |
| Brendon Stiles @BrendonStilesMD Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's support it as a community! #lcsm |
| #LCSM Chat @lcsmchat Thanks to our moderator @BrendonStilesMD for tonight’s chat! #LCSM |
| Tim Kruser @TimothyKruserMD Final thought relates to T5. STARS progam--amazing. We need to get some of these superstars at #ASTRO20. Can you say Miami?! #lcsm |
| Jean Parks @geekbabe RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @BrendonStilesMD: Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's s… |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @lcsmchat: Thanks to our moderator @BrendonStilesMD for tonight’s chat! #LCSM |
| #LCSM Chat @lcsmchat RT @IASLC: The registration deadline for the IASLC 2019 North America Conference on Lung Cancer has been extended to September 25! Register… |
| Gina @EAustin1969 The advances in both early detection and treatment options and spans is so amazing. We definitely have to badger, bother and pester to get more funding for more research so that many can live with this disease and not die #lcsm |
| Jose F. Corona-Cruz MD @drcoronacruz A4. Using them in early stage preoperatively is a great opportunity to check the surgical specimens and try to understand resistance mechanisms #LCSM |
| Brendon Stiles @BrendonStilesMD @JFreemanDaily @DrewMoghanaki @KAdvocate_LCAM I would watch this guy carefully... #lcsm |
| #LCSM Chat @lcsmchat RT @GinaHollenbeck: @BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward… |
| Jill Hamer-Wilson 🇨🇦 @JillHW #KRAS treatment AMG 510 shows some promise. More research needed. #LCSM #WCLC19 #hope #lungcancer |
| #LCSM Chat @lcsmchat RT @wildwestannie: Tomorrow marks the 21st anniversary of my Mom’s death from lung cancer. Treatment options and current research now were… |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb… |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's s… |
| Lung Cancer Research Foundation @lcrf_org The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm |
| Brendon Stiles @BrendonStilesMD @TimothyKruserMD Great point! #lcsm |
| KC Dill @kasedill @BrendonStilesMD As always thanks for the moderation and information. Lots of exciting news and hope from the conference. I look forward to our monthly chats. #LCSM #ResearchMatters |
| #LCSM Chat @lcsmchat RT @TimothyKruserMD: Final thought relates to T5. STARS progam--amazing. We need to get some of these superstars at #ASTRO20. Can you say M… |
| #LCSM Chat @lcsmchat RT @EAustin1969: The advances in both early detection and treatment options and spans is so amazing. We definitely have to badger, bother… |
| #LCSM Chat @lcsmchat RT @drcoronacruz: A4. Using them in early stage preoperatively is a great opportunity to check the surgical specimens and try to understand… |
| Brendon Stiles @BrendonStilesMD Thanks to everyone for participating! #lcsm |
| #LCSM Chat @lcsmchat RT @lcrf_org: The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm |
| Dave Bjork @bjork5 Thank you @IASLC and all the amazing lung cancer patient advocates who travel near and far for our community. And @BrendonStilesMD for hosting tonight. ❤️ #lcsm #community #gratitude |
| KC Dill @kasedill RT @lcrf_org: The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @GinaHollenbeck: @BrendonStilesMD There was a new assay test for ROS1 developed by Ventana. Relatively cheap and you get the results in… |
| Janet Freeman-Daily @JFreemanDaily RT @jillfeldman4: T5 So sorry...talking one of my college kids off the ledge. Will have to catch up later, but STARS was amazing thanks to… |
| Jose F. Corona-Cruz MD @drcoronacruz La investigación salva muchas vidas, necesitamos más investigadores y todos los recursos posibles #LCSM |
| Henning Willers, MD @HenningWillers Glad to have attended this chat. As always. Thanks & see you at #NACLC19 #LCSM |
| Drew Moghanaki @DrewMoghanaki @BrendonStilesMD @JFreemanDaily @KAdvocate_LCAM Thanks Janet. #lcsm |
| Laura Greco @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Anything else re treatment of oligoprogressive disease? #lcsm |
| Brendon Stiles @BrendonStilesMD @lcrf_org Great point. And the rapid pace is hard to keep up with. Thanks #lcsm and @lcsmchat for helping to keep patients, advocates, physicians, and researchers abreast. #lcsm |
| Drew Moghanaki @DrewMoghanaki @BrendonStilesMD I will. I will. #FOMO #lcsm @jillfeldman4 |
| Brendon Stiles @BrendonStilesMD @HenningWillers Awesome! I will be there and am counting on meeting you! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt… |
| Bob Steele @steele_bob Time to start reviewing all of the INFO links from tonight's excellent monthly Lung Cancer Social Media Twitter Chat Session. Cheers! #lcsm |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt… |
| Dave Bjork @bjork5 #RockStar #lcsm @BrendonStilesMD #research |
| Brendon Stiles @BrendonStilesMD How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD I will be standing by my poster 😇 #lcsm |
| I Wear Masks @wildwestannie RT @bjork5: #RockStar #lcsm @BrendonStilesMD #research https://t.co/1Ost0ACUIC |
| Bob Steele @steele_bob RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm |
| Drew Moghanaki @DrewMoghanaki RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD Thanks @BrendonStilesMD and all participating docs and patients for a great wrap-up of @IASLC #WCLC19. It gets better every year! Looking forward to next year in #Singapore ! #LCSM |
| Lung Cancer Research Foundation @lcrf_org RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm |
| Brendon Stiles @BrendonStilesMD Thanks everyone. Love the community and love learning from all of you! Signing off but hope to see or hear from everyone soon. #lcsm |
 | Jenni Chrysler @jenchrysler98 RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @GinaHollenbeck: @BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward… |
| Tim Kruser @TimothyKruserMD RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm |
| Jean Parks @geekbabe Thanks to all the Oncologists, researchers & pt advocates & our gracious host! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's s… |
| KC Dill @kasedill Thank you @IASLC for the research, hope and community!! #LCSM #ResearchMatters #EvidenceBasedMedicine |
| Janet Freeman-Daily @JFreemanDaily RT @TimothyKruserMD: Final thought relates to T5. STARS progam--amazing. We need to get some of these superstars at #ASTRO20. Can you say M… |
| Janet Freeman-Daily @JFreemanDaily RT @EAustin1969: The advances in both early detection and treatment options and spans is so amazing. We definitely have to badger, bother… |
| Bob Steele @steele_bob Good night all! Look forward to seeing you next month. #lcsm |
| Dave Bjork @bjork5 @JFreemanDaily @BrendonStilesMD @IASLC Thanks for being relentless. 🙌😊 #lcsm #research |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: A4. Using them in early stage preoperatively is a great opportunity to check the surgical specimens and try to understand… |
| Jill Hamer-Wilson 🇨🇦 @JillHW @BrendonStilesMD #STARS19 was a great program for those wanting to be more knowledgeable as research advocates. I was honoured to participate as a mentor. I would encourage #lungcancer #advocates to apply next year. What an opportunity! #LCSM #WCLC19 |
| Janet Freeman-Daily @JFreemanDaily RT @lcrf_org: The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm |
| Laura Greco @lgreco_ny @TimothyKruserMD Si! Get us funding to get there! #lcsm |
 | Dr. Amy C. Moore @acmoorephd It was an honor to partner with patient groups and our advocacy friends to disrupt the research paradigm at #WCLC19 #lcsm https://t.co/aFFvJZ9HUC |
| Janet Freeman-Daily @JFreemanDaily RT @drcoronacruz: La investigación salva muchas vidas, necesitamos más investigadores y todos los recursos posibles #LCSM https://t.co/N2… |
| Jean Parks @geekbabe @kasedill @StephenVLiu @IASLC I have a great Oncologist at @MGHCancerCenter #LCSM |
| Laura Greco @lgreco_ny RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm |
| Henning Willers, MD @HenningWillers @lgreco_ny @BrendonStilesMD @lcrf_org #ASTRO was allow about oligometastatic disease. Lots of promise to use #SABR , little data still. Nice study from @YaleCancer showing 10% systemic response rate with radiation #lcsm |